Hvivo, the pharmaceutical services company formerly known as Open Orphan, is to move to a new expanded facility in London on the back its “growing orderbook” and increased demand for its trial services.
The company, which specialises in testing infectious and respiratory disease products, has announced plans for a new consolidated facility at the fast-growing life sciences hub in Canary Wharf, London.
The expansion, funded by Hvivo clients, comes in response to the company’s “growing orderbook and increasing demand for its human challenge trial services”.
hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.
